4//SEC Filing
FRATES JAMES M 4
Accession 0000950170-24-027918
CIK 0001658551other
Filed
Mar 6, 7:00 PM ET
Accepted
Mar 7, 4:05 PM ET
Size
7.9 KB
Accession
0000950170-24-027918
Insider Transaction Report
Form 4
FRATES JAMES M
Chief Financial Officer
Transactions
- Sale
Common Stock
2024-03-05$18.73/sh−1,792$33,560→ 134,784 total
Holdings
- 11,072(indirect: By Trust)
Common Stock
- 15,459(indirect: By Trust)
Common Stock
Footnotes (5)
- [F1]Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.62 to $18.82. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F3]Reflects 15,459 shares previously reported as directly beneficially owned by the Reporting Person, which were transferred to the James M. Frates 2024 Grantor Retained Annuity Trust No. 1 on February 26, 2024 for no consideration. Such transfer constituted a change in form of beneficial ownership, exempted by Rule 16a-13 under the Securities Exchange Act of 1934, as amended.
- [F4]Shares held by the James M. Frates 2024 Grantor Retained Annuity Trust No. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
- [F5]Shares held by the FRATES FAMILY 2013 IRREV TRUST, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
Documents
Issuer
Amylyx Pharmaceuticals, Inc.
CIK 0001658551
Entity typeother
Related Parties
1- filerCIK 0001235598
Filing Metadata
- Form type
- 4
- Filed
- Mar 6, 7:00 PM ET
- Accepted
- Mar 7, 4:05 PM ET
- Size
- 7.9 KB